Man Group’s TherapeuticsMD TXMD Stock Holding History

Man Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-788	Closed	-$258K	–	2120
2018 Q3	$258K	Buy	788 +326	+71%	+$99.9K	﹤0.01%	1979
2018 Q2	$144K	Buy	+462	New	+$141K	﹤0.01%	2051

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Man Group's TXMD Position: Q4 2018 in Review

Man Group sold out of TherapeuticsMD (TXMD) in Q4 2018, closing a stake of 788 shares — an estimated $258K sold.

Man Group first reported a position in TXMD in Q2 2018 and held it in 2 quarters. The position peaked at $258K in Q3 2018. 140 funds tracked by Wall St. Rank hold TXMD as of Q4 2018.

Man Group reported no remaining TherapeuticsMD position as of Q4 2018 after selling out during the quarter.
Man Group sold 788 TherapeuticsMD shares in Q4 2018, an estimated $258K.
Man Group first reported a position in TherapeuticsMD in Q2 2018 and held it in 2 quarters.
Man Group's TherapeuticsMD position peaked at $258K in Q3 2018.
140 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2018.

Based on Man Group's 13F filing for Q4 2018, filed 14 Feb 2019.